Leerink Swann today maintained an Outperform rating on Biogen (NASDAQ: BIIB) and raised its price target to $271.00 (from $230.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE